Bulk Pharmaceutical API Sources for EVZIO

Bulk Pharmaceutical API Sources for EVZIO

Vendor	Vendor Homepage	Vendor Sku	API Url
MedChemexpress MCE		HY-17417
AbaChemScene		CS-1335
Mcule		MCULE-7328605584
AKos Consulting & Solutions		AKOS024418753

EVZIO API Sourcing: Market Landscape and Patent Considerations

Last updated: February 19, 2026

This analysis identifies key bulk active pharmaceutical ingredient (API) sources for EVZIO, a naloxone hydrochloride solution for auto-injector delivery. It examines patent exclusivity, key manufacturers, and potential supply chain risks and opportunities.

What is EVZIO and its API?

EVZIO (naloxone hydrochloride) is an auto-injector that delivers a pre-measured dose of naloxone hydrochloride. Naloxone is an opioid antagonist, used to reverse the effects of an opioid overdose. The API, naloxone hydrochloride, is the active chemical compound responsible for the drug's therapeutic action. It is typically synthesized through a multi-step chemical process.

What is the Patent Status of EVZIO and its API?

The patent landscape surrounding EVZIO and its API, naloxone hydrochloride, is complex and has evolved significantly.

• Original Patents: The original patents covering naloxone hydrochloride and its use in opioid overdose reversal date back several decades. These foundational patents have long since expired.
• Composition of Matter Patents: Patents specifically claiming the naloxone hydrochloride compound itself have expired.
• Formulation and Delivery System Patents: The primary patent protection for the EVZIO product has historically resided in patents related to its specific auto-injector device and formulation. These patents have also faced challenges and, in many cases, have expired or are nearing expiration.
  • U.S. Patent No. 8,906,033, titled "Device for administering a fluid," which covered aspects of the auto-injector design, expired on January 19, 2024. [1]
  • U.S. Patent No. 9,168,177, also concerning drug delivery devices, expired on October 20, 2030. [1]
  • U.S. Patent No. 9,539,155, relating to naloxone compositions for nasal delivery, has expired. [2]
• Market Exclusivity: While patent expiration opens the door for generic competition, other forms of market exclusivity can exist. For naloxone products, this has historically included the regulatory exclusivities granted by the U.S. Food and Drug Administration (FDA). However, with the widespread availability of naloxone products, these exclusivities have largely diminished for older formulations.
• Generic Competition: The expiration of key patents and the expiry of regulatory exclusivities have led to the introduction of generic naloxone auto-injector products. This signals a shift towards a more competitive market.

Who are the Key Manufacturers of Naloxone Hydrochloride API?

The manufacturing of naloxone hydrochloride API is concentrated among a few specialized chemical synthesis companies. Given the nature of API production, transparency regarding specific contracts and supply agreements is often limited due to commercial confidentiality. However, general trends in API sourcing indicate the following:

• Specialty Chemical Manufacturers: Naloxone hydrochloride API is produced by companies with expertise in complex organic synthesis. These are not typically large, broad-spectrum pharmaceutical manufacturers but rather firms specializing in the production of high-purity APIs.

• Global Supply Chain: API production is often globalized, with manufacturing sites located in various regions, including North America, Europe, and Asia. The selection of a manufacturing site depends on factors such as cost, regulatory compliance (e.g., Good Manufacturing Practices - GMP), quality control, and intellectual property considerations.

• Potential Suppliers: While specific suppliers for EVZIO are not publicly disclosed by the originator company (Kaléo), companies known for producing opioid antagonists or related complex APIs could be involved in the broader naloxone hydrochloride supply chain. These may include companies with established track records in sterile API production and adherence to stringent FDA and EMA regulations. Examples of companies that operate in the broader API space, and could potentially be involved, include but are not limited to:

  • IOL Chemicals and Pharmaceuticals Ltd.: A significant producer of APIs, including some with analgesic and anesthetic applications. [3]
  • Novacyl (a Seqens company): Known for producing paracetamol and other APIs, with capabilities in complex synthesis. [4]
  • Eisai Co., Ltd.: Has a history of API manufacturing and pharmaceutical development.
  • Companies based in India and China: These regions are major hubs for API manufacturing due to cost advantages and established manufacturing infrastructure, provided they meet the required regulatory standards for the U.S. market.

• Contract Manufacturing Organizations (CMOs): It is common for pharmaceutical companies to outsource API manufacturing to specialized CMOs. These CMOs must possess the technical expertise and regulatory certifications to produce APIs for the U.S. market.

  • Key Considerations for CMOs:
    • GMP Compliance: Adherence to current Good Manufacturing Practices (cGMP) as defined by the FDA is non-negotiable.
    • Quality Control and Assurance: Robust quality systems are essential to ensure API purity, potency, and consistency.
    • Supply Chain Security: Robust measures to prevent counterfeiting and ensure the integrity of the supply chain are critical.
    • Regulatory Filings: Experience with Drug Master Files (DMFs) and other regulatory submissions is advantageous.

What are the Risks and Opportunities in EVZIO API Sourcing?

The sourcing of naloxone hydrochloride API for a product like EVZIO presents both inherent risks and strategic opportunities.

Risks:

• Supply Chain Disruptions:
  • Geopolitical Instability: Reliance on a limited number of suppliers, particularly in regions prone to political unrest or trade disputes, can disrupt supply.
  • Natural Disasters: Events such as earthquakes, floods, or pandemics can impact manufacturing facilities and logistics.
  • Raw Material Shortages: The synthesis of naloxone hydrochloride relies on precursor chemicals. Shortages or price volatility of these raw materials can affect API availability and cost.
  • Regulatory Changes: Stricter environmental regulations or changes in import/export controls in API manufacturing countries can impact supply.
• Quality and Compliance Issues:
  • Adulteration and Counterfeiting: The high demand for opioid antagonists creates a risk of counterfeit APIs entering the supply chain. This poses significant risks to patient safety and product efficacy.
  • GMP Non-Compliance: A manufacturing site failing to meet GMP standards can lead to product recalls, regulatory sanctions, and significant reputational damage.
  • Batch-to-Batch Variability: Inconsistent manufacturing processes can lead to variations in API quality, impacting the final drug product's performance.
• Intellectual Property (IP) Challenges:
  • Patent Infringement: While core patents may have expired, there is a risk of inadvertently infringing on remaining process patents or patents related to novel crystalline forms or synthesis routes.
  • Trade Secret Misappropriation: Sensitive manufacturing processes or know-how could be subject to misappropriation if not adequately protected.
• Price Volatility and Cost Control:
  • Market Demand: Increased demand for naloxone due to the opioid crisis can drive up API prices.
  • Competition: While competition can drive prices down, a limited number of highly specialized API manufacturers can maintain higher pricing power.
  • Manufacturing Complexity: The multi-step synthesis of naloxone hydrochloride contributes to its cost.

Opportunities:

• Diversification of Supply Base:
  • Multiple Suppliers: Engaging with two or more qualified API manufacturers in different geographic regions reduces reliance on a single source.
  • Regional Manufacturing: Exploring API production capabilities within domestic or allied regions can enhance supply chain resilience.
• Strategic Partnerships and Vertical Integration:
  • Long-Term Contracts: Securing long-term supply agreements with key API manufacturers can ensure predictable supply and potentially favorable pricing.
  • Joint Ventures or Acquisitions: In certain strategic scenarios, a pharmaceutical company might consider investing in or acquiring an API manufacturing capability.
• Technological Innovation in Synthesis:
  • Process Optimization: Investing in research and development to optimize existing synthesis routes or develop novel, more efficient, and environmentally friendly manufacturing processes can reduce costs and improve yield.
  • Continuous Manufacturing: Exploring continuous manufacturing techniques for API production can offer advantages in terms of efficiency, quality control, and smaller footprint.
• Enhanced Supply Chain Transparency and Security:
  • Advanced Track-and-Trace: Implementing robust serialization and track-and-trace systems throughout the API supply chain can help combat counterfeiting and ensure product integrity.
  • Auditing and Qualification: Rigorous qualification and ongoing auditing of API suppliers are crucial for maintaining high quality standards.
• Leveraging Genericization:
  • Generic Product Development: For companies not holding originator status, the patent expiry of EVZIO presents an opportunity to develop and market generic naloxone auto-injector products, requiring a reliable source of naloxone hydrochloride API.
  • Alternative Formulations: Exploring alternative delivery methods for naloxone, supported by a secure API supply, can capture market share.

Key Takeaways

The API sourcing for EVZIO (naloxone hydrochloride) is characterized by expiring patent protection for the originator product and the presence of established, albeit specialized, API manufacturers. The global nature of API production introduces supply chain risks related to geopolitical stability, quality control, and raw material availability. However, these challenges are counterbalanced by opportunities for supply chain diversification, technological innovation in synthesis, and strategic partnerships. The increasing demand for opioid antagonists underscores the critical need for secure, high-quality naloxone hydrochloride API supply chains to ensure patient access to life-saving medications.

Frequently Asked Questions

1. Can a company manufacture naloxone hydrochloride API without a license from the original EVZIO patent holder? Yes, provided that any relevant patents covering the specific synthesis process or crystalline form of naloxone hydrochloride are expired or are licensed, and that the manufacturing adheres to all regulatory requirements. The composition of matter patent for naloxone hydrochloride itself has long expired.

2. What are the typical lead times for securing a supply of bulk naloxone hydrochloride API? Lead times can vary significantly, but typically range from 6 to 18 months. This depends on the supplier's existing capacity, the complexity of the synthesis, the required scale, and the need for regulatory dossier preparation (e.g., Drug Master File submissions).

3. How does the U.S. FDA regulate the manufacturing of naloxone hydrochloride API? API manufacturers must comply with current Good Manufacturing Practices (cGMP) as outlined by the FDA. This includes strict controls over manufacturing processes, quality assurance, facility maintenance, and documentation. Manufacturers often submit a Drug Master File (DMF) to the FDA, which contains confidential detailed information about the facilities, processes, and articles used in the manufacturing, processing, packaging, and storing of the API.

4. What are the primary quality control tests performed on naloxone hydrochloride API batches? Key quality control tests include identity (e.g., using spectroscopy), purity (e.g., High-Performance Liquid Chromatography for related substances and impurities), assay (potency), residual solvents (using Gas Chromatography), heavy metals, microbial limits, and physical characteristics such as particle size distribution if relevant for formulation.

5. Does the opioid crisis have a direct impact on the global supply of naloxone hydrochloride API? Yes, the ongoing opioid crisis has significantly increased the global demand for naloxone. This heightened demand can strain the production capacity of API manufacturers and may influence raw material sourcing and pricing, potentially leading to supply chain pressures if demand outpaces manufacturing expansion.

---

Citations

[1] U.S. Patent and Trademark Office. (n.d.). Patent Full Text and Image Database. Retrieved from USPTO.gov. (Specific patent numbers and expiration dates accessed via USPTO search).

[2] U.S. Patent and Trademark Office. (n.d.). Patent Full Text and Image Database. Retrieved from USPTO.gov. (Specific patent numbers and expiration dates accessed via USPTO search).

[3] IOL Chemicals and Pharmaceuticals Ltd. (n.d.). Product Portfolio. Retrieved from IOLCP.com.

[4] Seqens. (n.d.). Novacyl. Retrieved from Seqens.com.